eoadjuvant anti PD-1 immunotherapy in resectable non-small cell lung cancer - NEOM

AIO-Studien-gGmbH0 个研究点目标入组 30 人开始时间: 2017年4月11日最近更新: 2019年2月28日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: AIO-Studien-gGmbH
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•1. Cooperation and willingness to complete all aspects of the study
•2. Signed and dated written informed consent must be given prior to study inclusion
•3. Histological or cytological confirmed NSCLC.
•4. Clinical stage II-IIIA according to the TNM classification, 7th edition.
•stage IIIa: T1/T2 N2 (IIIa1-3 Robinson classification)
•5. Adequate disease staging by PET/CT performed and resectability established.
•6. At least 1 measurable lesion according to RECIST 1.1
•7. Age = 18 years
•8. ECOG performance status 0 - 1
•9. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in in the protocol, for the course of the study through 120 days after the last dose of study medication.
•Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
•Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
•10. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in protocol, starting with the first dose of study therapy through 120 days after the last dose of study therapy.
•Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
•11. Adequate bone marrow function, liver and renal function:
•a. Absolute neutrophil count = 1.5 x 10^9/L
•b. Thrombocytes = 100 x 10^9/L
•c. Hemoglobin = 9 g/dL without transfusion or EPO dependency (within 7 days of assessment)
•d. INR < 1.4 ULN and PTT < 40 seconds during the last 7 days before therapy
•e. Bilirubin < 1.5 x upper limit of normal
•f. AST (GOT) and ALT (GPT) < 2.5 x ULN
•g. Albumin = 2.5 mg/dL
•h. Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl):
•=1.5 X upper limit of normal (ULN) OR
•=60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
•12. Adequate lung and cardiac function for intended lung resection according to German S3 guideline
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

排除标准

•1. Anticancer treatment during the last 30 days prior to start of treatment, including systemic therapy, radiotherapy or major surgery
•2. Participation in a clinical trial within the last 30 days prior to study treatment
•3. History of allogeneic tissue/solid organ transplant
•4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
•5. Evidence of interstitial lung disease.
•6. cT4 tumor
•7. Symptomatic acute cardiovascular or cerebrovascular disease
•8. Known active HBV, HCV or HIV infection
•9. Has any other active infection requiring systemic therapy.
•10. Patients with active tuberculosis
•11. Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-Programmed cell death-ligand 1 (anti-PD-L1), anti-PD-L2, anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
•12. A diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
•13. Patient has had a prior monoclonal antibody within 4 weeks prior to study Day 1
•14. Patient has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to a previously administered agent. [Note: Subjects with = Grade 2 neuropathy are an exception to this criterion and may qualify for the study. If subject received major surgery, he/she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.]
•15. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjorgen’s syndrome will not be excluded from the study.
•16. Has received a live vaccine within 30 days prior to the first dose of trial treatment. [Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.]
•17. Has known hypersensitivity to pembrolizumab or any of constituents of the product.
•18. Other active malignancy requiring treatment
•Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
•19. Lactating or pregnant women, women of child-bearing potential who do not agree to the usage of highly effective contraception methods (allowed methods o

研究者

发起方

AIO-Studien-gGmbH

相似试验

进行中（未招募）

1 期

Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resectioStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004944-37-PLMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

进行中（未招募）

1 期

EUCTR2014-004944-37-FIMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

进行中（未招募）

1 期

EUCTR2014-004944-37-DKMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

进行中（未招募）

1 期

EUCTR2014-004944-37-GBMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co. Inc900

招募中

1 期

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma GroupStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864

CTIS2023-509136-25-00Merck Sharp & Dohme LLC1,019